Navigation Links
EUCelLEX Project: Assessment of the social issues raised by the use of regenerative medicine in Euro
Date:12/9/2013

The purpose is to submit the data obtained to the European Commission for it to draw up legislative measures in line with medical advances in this field. On 4 December the nine research teams in Europe and Canada met at the Political Sciences Research Centre in Paris (CEVIPOF) for the launching of the project.

Biobanks: the future of regenerative medicine

Today, human biological specimens are seen as resources essential to advances in the life sciences and medicine. The analytical data obtained enable a better understanding of the various diseases and also make it possible to propose the appropriate treatment, notably in the field of regenerative medicine . Gathering, storing, processing and distributing them are all done by the biobanks - key players in the transfer of scientific knowledge to clinical practice. These biological databanks will enable researchers to identify new clinical biomarkers and develop new therapeutic approaches such as regenerative medicine. In this field, research into stem cells continues to be promising, stimulating as it does the body's self-healing ability.

Need for a legal definition of the use of human biological specimens at European level

From 2004 to 2006, the European Union adopted three directives governing cells and human tissues in order to standardise their acquisition, their storage and their use for therapeutic purposes. These directives apply specifically to tissue and cell banks, including cord blood strains and cells used for regenerative medicine. However, they were used in very different ways from one country to another. "At present, the European legal texts concerning the use of stem cells for research by the players in the public and private sectors are not such as to enable the efficient sharing of these resources in Europe, which may impede advances in research," explains Emmanuelle Rial-Sebbag, coordinator of the EUCelLEX Project.

Furthermore, scientific developme
'/>"/>

Contact: Emmanuelle Rial-Sebbag
rialseb@cict.fr
33-056-114-5616
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. CNIO participates in the ENCODE project: A stride forward in biomedical research
2. EU project: Searching for exotics in the shrimp nets
3. Expert assessment: Sea-level rise could exceed 1 meter in this century
4. Risk assessment team on Bt plants wins Integrated Pest Management Award
5. First risk assessment of shale gas fracking to biodiversity
6. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
7. Health impact assessments prove critical public health tool
8. First global assessment of land and water grabbing published in national journal
9. Triage for plants: NYBG scientists develop and test rapid species conservation assessment technique
10. UCLA research makes possible rapid assessment of plant drought tolerance
11. UC Santa Barbara researchers play key role in UN Environmental Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... Scientists are reporting a new technique for mapping ... collected from the field and returned to a lab ... neither is readily available during a clean-up operation. The ... accurately predict the total amount of petroleum contaminants in ...
... bring forth the best properties of both ever since ... Age. In the latest successful merger, researchers at the ... of Maryland (UM) and the U.S. Food and Drug ... substances that individually have generated interest for their potential ...
... Cambridge, Md. (June 9, 2010) A team of scientists ... Point Laboratory will travel to the Gulf of Mexico later ... Horizon oil spill on plankton and fish communities in the ... Rapid Response Research (RAPID) grant for the expedition, which will ...
Cached Biology News:Predicting amount of oil in contaminated soils 2Liposome-hydrogel hybrids: No toil, no trouble for stronger bubbles 2
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... a Medicare Part D provider, with offices in New ... the company and ProCare, its former pharmacy benefit manager, ... ProCare based on Fox,s allegations of negligence and breach ... of Fox Insurance Company commented: "Fox Insurance is gratified ...
... Pharmaceuticals, Inc. announced today that data from ENGAGE ... novel, oral small molecule inhibitor of class I histone ... with relapsed or refractory Hodgkin,s lymphoma (HL).  This data ... 8:00 PM PT at the American Society of ...
... Life Technologies Corporation today announced that its Ion Personal ... Innovative New Product "MIP" Awards luncheon hosted by CONNECT in ... disruptive technology in the gene sequencing field. Since ... uptake in research labs around the world and has been ...
Cached Biology Technology:Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 2Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 3